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SUMMARY
Hsp104 is an AAA+ protein disaggregase, which can be potentiated via diverse mutations in its 
autoregulatory middle domain (MD) to mitigate toxic misfolding of TDP-43, FUS, and α-
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synuclein implicated in fatal neurodegenerative disorders. Problematically, potentiated MD 
variants can exhibit off-target toxicity. Here, we mine disaggregase sequence space to safely 
enhance Hsp104 activity via single mutations in nucleotide-binding domain 1 (NBD1) or NBD2. 
Like MD variants, NBD variants counter TDP-43, FUS, and α-synuclein toxicity and exhibit 
elevated ATPase and disaggregase activity. Unlike MD variants, non-toxic NBD1 and NBD2 
variants emerge that rescue TDP-43, FUS, and α-synuclein toxicity. Potentiating substitutions 
alter NBD1 residues that contact ATP, ATP-binding residues, or the MD. Mutating the NBD2 
protomer interface can also safely ameliorate Hsp104. Thus, we disambiguate allosteric regulation 
of Hsp104 by several tunable structural contacts, which can be engineered to spawn enhanced 
therapeutic disaggregases with minimal off-target toxicity.
In Brief
Tariq et al. disambiguate the allosteric regulation of Hsp104 by several tunable structural contacts, 
which can be engineered to spawn enhanced therapeutic disaggregases with minimal off-target 
toxicity. Non-toxic nucleotide-binding domain 1 (NBD1) and NBD2 variants emerge that rescue 
TDP-43, FUS, and α-synuclein toxicity connected to neurodegenerative disease.
Graphical Abstract
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INTRODUCTION
Aberrant protein aggregation is linked with several neurodegenerative disorders, including 
amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson’s 
disease (PD) (Chuang et al., 2018). In ALS-FTD, subsets of patients display cytoplasmic 
aggregation of TDP-43 or FUS in degenerating neurons (Robberecht and Philips, 2013). 
TDP-43 and FUS are RNA-binding proteins with prion-like domains, which shuttle between 
the nucleus and cytoplasm (Harrison and Shorter, 2017). However, cytoplasmic TDP-43 or 
FUS aggregation in disease restricts their transport back to the nucleus. Dissolution of 
cytoplasmic TDP-43 and FUS aggregates and restoration of functional TDP-43 and FUS to 
the nucleus is a major therapeutic goal in ALS-FTD (Guo et al., 2019). In PD, α-synuclein 
(α-syn) forms toxic soluble oligomers and amyloid fibrils that accumulate in cytoplasmic 
Lewy bodies and neurites in degenerating dopaminergic neurons (Abeliovich and Gitler, 
2016). α-Syn is a lipid-binding protein that typically localizes to the plasma membrane but 
forms cytoplasmic inclusions in PD patients and in yeast (Outeiro and Lindquist, 2003). 
Inclusions of α-syn, TDP-43, and FUS are widely considered intractable. Moreover, the 
genes encoding TDP-43 and FUS are essential (Ling et al., 2013), and severe depletion of α-
syn from nigrostriatal neurons might elicit degeneration (Collier et al., 2016). Thus, 
strategies that decrease expression or promote degradation of these proteins may be 
counterproductive, and reactivation of these proteins is an intriguing alternative approach 
(Guo et al., 2018, 2019; Jackrel et al., 2014a; Jackrel and Shorter, 2017; Shorter, 2016, 
2017).
Hsp104 is a hexameric AAA+ protein disaggregase found in yeast, which harbors an N-
terminal domain (NTD), nucleotide-binding domain 1 (NBD1), a middle domain (MD), 
NBD2, and a short C-terminal domain (CTD; Figure 1A). Hsp104 resolves diverse protein 
aggregates (Shorter and Southworth, 2019; Sweeny and Shorter, 2016). Following 
environmental stress, Hsp104 solubilizes aggregated proteins (Parsell et al., 1994; Wallace et 
al., 2015). Additionally, Hsp104 constructs and deconstructs yeast prions (infectious 
amyloids) for adaptive purposes (DeSantis et al., 2012; DeSantis and Shorter, 2012; Klaips 
et al., 2014; Newby and Lindquist, 2013; Park et al., 2014; Paushkin et al., 1996; Shorter and 
Lindquist, 2004, 2006, 2008; Sweeny et al., 2015; Zhao et al., 2017). The remarkable ability 
of Hsp104 to dissolve prions is intriguing, as prions are commonly perceived as 
ineradicable. We have suggested that Hsp104 could be applied to eliminate aggregated 
species and toxic, soluble oligomers linked to neurodegeneration (March et al., 2019; 
Shorter, 2008). Indeed, Hsp104 actively remodels amyloids and toxic soluble oligomers 
formed by several disease-linked proteins (Castellano et al., 2015; DeSantis et al., 2012; Liu 
et al., 2011; Lo Bianco et al., 2008; Michalska et al., 2019; Park et al., 2017). Importantly, 
Hsp104 antagonizes protein misfolding and neurodegeneration in animal models of 
neurodegenerative disease (Cushman-Nick et al., 2013; Lo Bianco et al., 2008; Satyal et al., 
2000; Vacher et al., 2005). Nonetheless, Hsp104 activity against many amyloidogenic 
substrates has limits, and effective remodeling can require high Hsp104 concentrations 
(DeSantis et al., 2012; Lo Bianco et al., 2008). Moreover, Hsp104 displays limited activity 
against TDP-43 and FUS (Jackrel et al., 2014a). TDP-43, FUS, and α-syn do not have yeast 
homologs and are not natural Hsp104 substrates. Thus, we have engineered Hsp104 via 
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diverse single missense mutations in its autoregulatory MD to potentiate activity against 
various disease-linked proteins (Castellano et al., 2015; Jackrel et al., 2014a, 2015; Jackrel 
and Shorter, 2014; Ryan et al., 2019; Tariq et al., 2018).
Potentiated Hsp104 MD variants display a therapeutic gain of function. They rescue 
TDP-43, FUS, and α-syn aggregation and toxicity in yeast under conditions in which wild-
type Hsp104 is ineffective (Mack and Shorter, 2016). Certain enhanced MD variants 
suppress TDP-43, FUS and α-syn mislocalization and rescue dopaminergic 
neurodegeneration in a C. elegans PD model (Jackrel et al., 2014a; Yasuda et al., 2017). 
Potentiated MD variants disassemble TDP-43, FUS, and α-syn fibrils more effectively than 
Hsp104 (Jackrel et al., 2014a). Problematically, however, potentiated MD variants can 
exhibit off-target toxicity (Jackrel et al., 2014a). This off-target toxicity refers to adverse 
effects on targets other than those desired (i.e., TDP-43, FUS, or α-syn) because of limited 
substrate specificity.
The MD is just one domain of Hsp104, and vast tracts of Hsp104 sequence space remain 
unexplored and poorly understood. Here, we establish that Hsp104 can be more safely 
potentiated to counter ALS-FTD-linked and PD-linked proteotoxicity by single missense 
mutations in NBD1 or NBD2. To do so, we exploited yeast-based screens to hack 
disaggregase sequence space. We have isolated several non-toxic, potentiated Hsp104 
variants with single missense mutations in NBD1 or NBD2. We thus expand the repertoire 
of mutations that enhance Hsp104 activity and illuminate several critical contacts that 
allosterically tune Hsp104 activity. Our studies open a gateway to synthetic, non-toxic 
disaggregases with therapeutic utility.
RESULTS
Specific Missense Mutations in NBD1 Potentiate Hsp104
Yeast models of α-syn, TDP-43, and FUS proteinopathy have been established in which the 
proteins are overexpressed through a galactose-inducible promoter. α-Syn, TDP-43, and 
FUS overexpression is toxic and the proteins accumulate in cytoplasmic inclusions, 
recapitulating phenotypes of PD and ALS-FTD patients (Johnson et al., 2008; Outeiro and 
Lindquist, 2003; Sun et al., 2011). However, Hsp104 cannot rescue this aggregation and 
toxicity, providing a platform to screen for Hsp104 variants with enhanced activity (Jackrel 
et al., 2014a). A key feature of this screen is that overtly toxic, hyperactivated Hsp104 
variants will not survive the selection process. Rather, the screen selects for Hsp104 variants 
that are not toxic at 30°C and rescue α-syn, TDP-43, or FUS toxicity. We have used this 
strategy to isolate MD variants that suppress α-syn, TDP-43, and FUS toxicity (Jackrel et 
al., 2014b). We implemented a similar approach to uncover potentiated NBD1 or NBD2 
variants. Thus, we used domain-specific error-prone PCR to randomly mutagenize NBD1 or 
NBD2 while leaving the remainder of the Hsp104 gene unperturbed. We achieved a 
mutation rate of approximately one mutation per gene. To isolate potentiated variants, we 
co-expressed these Hsp104 variant libraries with α-syn, TDP-43, or FUS in yeast. Thus, we 
identified a series of NBD1 variants that potently suppress α-syn, TDP-43, and FUS 
toxicity. We subsequently validated eight NBD1 variants: Hsp104I187F, Hsp104E190V, 
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Hsp104I193L, Hsp104I193T, Hsp104I230N, Hsp104Q347L, Hsp104L355A, and Hsp104E360K 
(Figure 1A).
Potentiated NBD1 Variants Suppress α-Syn Toxicity, Aggregation, and Mislocalization
Not any mutation in NBD1 potentiates Hsp104 (Torrente et al., 2016). For example, 
Hsp104A178D and Hsp104T196S, like Hsp104, had no effect on α-syn toxicity (Figure 1B). In 
contrast, Hsp104I187F and Hsp104E360K very strongly suppressed α-syn toxicity, rescuing at 
a similar level as Hsp104A503V (Figures 1B and S1A), a potentiated variant bearing a 
mutation in MD helix L3 (Jackrel et al., 2014a). Hsp104I230N and Hsp104L355A strongly 
suppressed α-syn toxicity (Figures 1B and S1A). Hsp104Q347L and Hsp104I193T displayed a 
slightly weaker rescue, and Hsp104E190V and Hsp104I193L displayed the least rescue 
(Figures 1B). Rescue of α-syn toxicity was not due to altered expression levels, as α-syn 
and Hsp104 levels were roughly equal across the strains (Figures 1C and S1B).
We also tested whether Hsp104A330V could rescue α-syn toxicity, as the equivalent mutation 
in the E. coli Hsp104 homolog, ClpB, has been reported to hyperactivate ClpB (Franke et 
al., 2017). However, Hsp104A330V only very slightly reduced α-syn toxicity (Figure S1A). 
Thus, mutations that hyperactivate ClpB do not necessarily translate to Hsp104 variants able 
to potently suppress α-syn toxicity.
A potentiated MD variant, Hsp104A503V, suppresses formation of cytoplasmic α-syn foci 
and enables α-syn to localize to the plasma membrane, whereas Hsp104 is ineffective 
(Jackrel et al., 2014a). We tested the NBD1 variants and found that Hsp104I187F and 
Hsp104E360K, like Hsp104A503V, suppress formation of cytoplasmic foci and restore α-syn 
to the plasma membrane (Figures 1D and 1E). Upon overexpression of Hsp104I187F and 
Hsp104E360K, more than 70% of cells displayed α-syn solely localized to the plasma 
membrane, compared with ~30% of cells expressing Hsp104 (Figure 1E). In contrast, ~47% 
of cells expressing Hsp104I230N and ~54% of cells expressing Hsp104Q347L harbored 
cytoplasmic α-syn inclusions (Figure 1E). Thus, Hsp104 variants that provided the strongest 
rescue of α-syn toxicity also provided the greatest reduction in α-syn aggregation (Figures 
1B and 1E).
Potentiated NBD1 Variants Suppress TDP-43 Toxicity, Aggregation, and Mislocalization
The same NBD1 variants that potently suppress α-syn toxicity also suppress TDP-43 
toxicity but display slightly different trends. As with α-syn, Hsp104, Hsp104A178D, and 
Hsp104T196S were ineffective (Figure 2A). In contrast, Hsp104I230N, Hsp104E360K, and 
Hsp104L355A confer the strongest rescue of TDP-43 toxicity (Figures 2A and S1A). 
Hsp104I187F and Hsp104Q347L confer a weaker rescue, while Hsp104E190V, Hsp104I193T, 
and Hsp104I193L confer a very weak rescue (Figures 2A and S1A). Hsp104A330V failed to 
rescue TDP-43 toxicity (Figure S1A). As with α-syn, rescue of TDP-43 toxicity was not due 
to altered expression levels, as TDP-43 and Hsp104 levels were roughly equal across strains 
(Figures 2B and S1B).
TDP-43 shuttles between the nucleus and cytoplasm but aggregates and mislocalizes in the 
cytoplasm of degenerating neurons of ALS-FTD patients (Guo and Shorter, 2017). 
Expression of TDP-43 in yeast recapitulates this phenotype (Johnson et al., 2008). 
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Hsp104A503V suppresses formation of cytoplasmic TDP-43 foci and restores TDP-43 to the 
nucleus (Jackrel et al., 2014a). The NBD1 variants Hsp104I187F, Hsp104I230N, 
Hsp104Q347L, and Hsp104E360K reduced cytoplasmic TDP-43 foci and increased nuclear 
localization (Figures 2C and 2D). Indeed, ~53% of cells expressing Hsp104I187F or ~50% of 
cells expressing Hsp104E360K displayed nuclear TDP-43, while only ~24% of cells 
expressing Hsp104 or ~31% of cells with the vector control displayed nuclear TDP-43 
(Figures 2C and 2D). Yeast coexpressing Hsp104I230N or Hsp104Q347L displayed slightly 
fewer cells with nuclear TDP-43 (~49% for I230N and ~47% for Q347L) than the other 
potentiated variants (Figures 2C and 2D). Thus, Hsp104I187F, Hsp104I230N, Hsp104Q347L, 
and Hsp104E360K are potent suppressors of TDP-43 aggregation and toxicity. Clearing 
cytoplasmic TDP-43 aggregates and restoring TDP-43 to the nucleus is anticipated to be 
highly therapeutic for ALS-FTD (Gasset-Rosa et al., 2019; Mann et al., 2019; McGurk et 
al., 2018a, 2018b).
Potentiated NBD1 Variants Suppress FUS Toxicity and Aggregation
As with TDP-43, Hsp104I230N and Hsp104E360K conferred the strongest rescue of FUS 
toxicity, comparable with the rescue by Hsp104A503V, whereas Hsp104, Hsp104A178D, and 
Hsp104T196S were ineffective (Figures 3A and S1A). Hsp104I187F, Hsp104Q347L, 
Hsp104I193T, and Hsp104L355A were slightly less robust suppressors of FUS toxicity 
(Figures 3A and S1A). Hsp104E190V and Hsp104I193L displayed very mild rescue of FUS 
toxicity (Figure 3A). Hsp104A330V displayed minimal rescue of FUS toxicity (Figure S1A). 
Although some enhanced Hsp104 variants (e.g., Hsp104I187F) appeared to reduce FUS 
levels, in other cases enhanced Hsp104 variants (e.g., Hsp104I193T and Hsp104L355A) did 
not (Figures 3B and S1B). Thus, rescue of FUS toxicity by Hsp104 variants does not require 
reduced FUS protein levels (Figures 3B and S1B; Jackrel et al., 2014a; Jackrel and Shorter, 
2014).
Hsp104A503V disaggregates FUS inclusions (Jackrel et al., 2014a; Yasuda et al., 2017). 
Thus, we tested if NBD1 variants also antagonize FUS aggregation. Upon overexpression of 
FUS, ~75% of cells contain multiple foci, and Hsp104 had no effect on this phenotype 
(Figures 3C and 3D). Hsp104A503V reversed this phenotype, clearing foci entirely from 
~73% of cells. In contrast, Hsp104I187F and Hsp104E360K decreased the percentage of cells 
containing multiple foci to ~18% while increasing the percentage of cells with a single focus 
to ~30% (Figures 3C and 3D). More than 50% of these cells were cleared of foci entirely 
(Figures 3C and 3D). Hsp104I230N and Hsp104Q347L increased the percentage of cells with a 
single focus even further to ~38% (Figures 3C and 3D). FUS foci were cleared entirely from 
~40% of cells expressing Hsp104I230N and ~27% of cells expressing Hsp104Q347L (Figure 
3C and Figure 3D). Unlike TDP-43, FUS is not returned to the nucleus, as the yeast nuclear-
import machinery does not recognize the FUS PY-NLS (Guo et al., 2018; Ju et al., 2011; 
Sun et al., 2011). Nonetheless, Hsp104I187F, Hsp104I230N, Hsp104Q347L, and Hsp104E360K 
antagonize FUS aggregation and toxicity.
Potentiated NBD1 Variants Typically Do Not Exhibit Reduced Growth at 37°C
Potentiated Hsp104 MD variants often confer a temperature-sensitive growth phenotype in 
which yeast grow normally at 30°C but exhibit reduced growth at 37°C (Jackrel et al., 
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2014a). This off-target toxicity likely stems from promiscuous substrate recognition 
resulting in unfolding of essential proteins (Jackrel et al., 2014a; Jackrel and Shorter, 2014; 
Schirmer et al., 2004). Thus, we determined if the NBD1 variants also conferred this 
phenotype. Hsp104I193T, Hsp104I230N, Hsp104Q347L, and Hsp104L355A exhibited similar 
growth to Hsp104 at 37°C, whereas Hsp104E360K exhibited minimally reduced growth at 
37°C (Figure 3E). In contrast, Hsp104I187F displayed a strong growth defect at 37°C that 
was more severe than the potentiated MD variant, Hsp104A503V (Figure 3E). Aside from 
Hsp104I187F and to a lesser extent Hsp104E360K, the potentiated NBD1 variants were more 
like Hsp104 and did not display a temperature-sensitive growth phenotype. Thus, Hsp104 
activity can be potentiated via specific mutations in NBD1 without conferring undesirable 
toxicity, which contrasts with potentiated MD variants that typically exhibit toxicity in yeast 
at 37°C.
Hsp104A330V was an outlier, which we studied because the equivalent mutation 
hyperactivates ClpB (Franke et al., 2017). Hsp104A330V fails to rescue TDP-43 toxicity and 
confers negligible rescue of FUS and α-syn toxicity (Figure S1A). However, Hsp104A330V 
was subtly toxic to yeast at 30°C (unlike Hsp104I187F) and more toxic than Hsp104A503V at 
37°C (Figure 3E). Thus, Hsp104A330V is likely hyperactive with severe off-target effects. 
However, this hyperactivity is not coupled to an ability to potently rescue TDP-43, FUS, and 
α-syn toxicity. Thus, we reserve the term “potentiated” (i.e. endowed with greater potency) 
for Hsp104 variants able to potently rescue TDP-43, FUS, or α-syn toxicity, whereas we 
reserve the term “hyperactive” (i.e. more active than desired) for Hsp104 variants that are 
toxic to yeast at 30°C and 37°C and have extremely limited ability to rescue TDP-43, FUS, 
or α-syn toxicity. Aside from Hsp104A330V, the only other hyperactive Hsp104 variants we 
have encountered are Hsp104E360P (see below) and Hsp104A503P (Jackrel et al., 2014a).
Potentiating Substitutions Alter NBD1 Residues that Contact ATP, ATP-Binding Residues, 
or the MD
We next mapped the potentiating mutations onto the structure of Hsp104 hexamers bound to 
AMP-PNP or ADP (Figures 4A–4F; Gates et al., 2017; Yokom et al., 2016). E190 and I193 
are highly conserved residues (Figure 4G) that reside in helix B3 (Figures 4C and 4D). 
Interestingly, in the AMP-PNP-bound structure, E190 lies in close proximity to R419 in 
helix L1 of the MD of the counterclockwise protomer (Figure 4C, left; Yokom et al., 2016). 
The E190V mutation would likely alter this inter-protomer interaction with the MD. 
However, the R419V mutation did not potentiate Hsp104 (Figure S2A), and R419M 
inhibited Hsp104 activity (Wendler et al., 2007). Thus, the mechanism of potentiation is 
likely more complex than simply disrupting this NBD1:MD interaction. Indeed, I193 also 
interacts with E190 in the ADP-bound structure (Figure 4D, right). Thus, alteration of E190 
or I193 may also affect their interaction within NBD1 and elicit enhanced activity.
I187 is a highly conserved residue (Figure 4G) that lies in a loop between helix B2 and B3 
of the NBD1 large domain (Figure 4E). The carbonyl oxygen of the main chain at position 
I187 directly contacts nucleotide in the AMP-PNP- and ADP-bound structures (Figure 4E; 
Gates et al., 2017; Lee et al., 2003; Yokom et al., 2016). Thus, alteration of this side chain 
likely alters the architecture and regulation of the nucleotide-binding pocket.
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I230 is a highly conserved residue in helix B4, which also carries the critical K218 Walker A 
residue at its N-terminal end (Figures 4F and 4G). I230 is in close proximity to R495 in the 
MD in the ADP-bound hexamer (Figure 4F, right). Hence, the I230N mutation may disrupt 
this contact and confer potentiation. Indeed, R495D, R495E, R495N, and R495M also 
potentiate Hsp104 (Figure S2A), and R495M elevates Hsp104 ATPase activity (Wendler et 
al., 2007). Thus, the I230N mutation likely perturbs an intra-protomer NBD1:MD 
interaction in the ADP-bound hexamer.
Q347 is a poorly conserved residue in helix C1 of the NBD1 small domain (Figures 4E and 
4G). In fact, glutamate or aspartate is typically found at this position in Hsp104 homologs, 
indicating a divergent feature of S. cerevisiae Hsp104 (Figure 4G). Q347 contacts I351, an 
ATP-binding residue (Figure 4E; Gates et al., 2017; Lee et al., 2003; Yokom et al., 2016). 
Thus, alteration of the Q347 side chain may alter regulation of the nucleotide-binding 
pocket.
L355 is a highly conserved residue in helix C1 of the NBD1 small domain (Figures 4F and 
4G). L355 helps confine nucleotide within the binding pocket (Figure 4F; Lee et al., 2003). 
Thus, the L355A mutation likely alters the architecture and regulation of the nucleotide-
binding pocket.
E360 is a highly conserved residue also in helix C1 (Figures 4C and 4G). In the AMP-PNP-
bound hexamer, E360 lies in proximity to R433 in the distal loop between helix L1 and L2 
of the MD of the counterclockwise protomer (Figure 4C, left; Yokom et al., 2016). The 
E360K mutation would likely alter this inter-protomer NBD1:MD interaction. However, 
R433E, R433K, and R433Y did not potentiate Hsp104 (Figure S2A). Thus, disruption of the 
E360:R433 contact is likely not critical for enhanced activity. In the ADP-bound hexamer, 
E360 lies in proximity to K480 in MD helix L2 of the same protomer (Figure 4C, right; 
Gates et al., . Thus, the E360K mutation would disrupt this intra-protomer NBD1:MD 
contact. Importantly, K480E also enables Hsp104 to rescue α-syn, TDP-43, and FUS 
toxicity, although rescue of TDP-43 toxicity was not as strong as E360K, perhaps because of 
lower expression of Hsp104K480E compared to Hsp104E360K (Figures S2A and S2B; Jackrel 
et al., 2015). Breaking the intra-protomer NBD1:MD contact between E360 and K480 in the 
ADP-bound hexamer likely elicits potentiated Hsp104 activity.
Diverse Mutations at Certain NBD1 Positions Potentiate Hsp104
At several MD positions, Hsp104 can be mutated to diverse amino acids and confer 
potentiation. For example, A503 can be mutated to any amino acid, except proline to 
suppress α-syn, FUS, and TDP-43 toxicity (Jackrel et al., 2014a). We were curious if the 
NBD1 variants also displayed this degeneracy. Thus, we introduced conservative or non-
conservative mutations at several of the potentiating NBD1 sites. We mutated Hsp104I187, 
Hsp104I230, Hsp104Q347, and Hsp104E360 to nine or ten different residues with different 
properties. Interestingly, none of these NBD1 positions displayed the same level of 
degeneracy as A503 to yield potentiated activity. Thus, more specific effects dictate which 
mutations in NBD1 enhance activity.
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Hsp104I187X (where X represents any amino acid) displayed the strongest rescue of α-syn, 
TDP-43, and FUS toxicity when mutated to aromatic residues phenylalanine, tryptophan, or 
tyrosine (Figure 5A). Valine did not confer potentiation, possibly because this side chain is 
not sufficiently different from isoleucine (Figure 5A). Indeed, valine is often found at this 
position in Hsp104 homologs (data not shown). In contrast, Hsp104I187A and Hsp104I187S 
rescued α-syn, TDP-43, and FUS toxicity (Figures 5A). Mutation to asparagine enabled 
some rescue of α-syn and FUS toxicity but not TDP-43 toxicity (Figure 5A). Substitution 
with aspartate, lysine, or proline abolished rescue (Figure 5A). Thus, alteration of this 
nucleotide-binding residue can have diverse effects on Hsp104 activity. Charged 
substitutions at I187 do not potentiate activity, whereas aromatic substitutions broadly 
enhance activity. Moreover, mutation of I187 to alanine or serine mildly increases activity, 
whereas mutation of I187 to asparagine tunes Hsp104 to selectively antagonize α-syn and 
FUS toxicity. Notably, Hsp104I187F/Y/W exhibited off-target toxicity at 37°C, whereas 
Hsp104I187A/S/N did not (Figure S3A).
Hsp104I230X displayed the strongest rescue of α-syn, TDP-43, and FUS toxicity when 
mutated to asparagine, serine, aspartate, glutamine, or phenylalanine (Figure 5B). 
Hsp104I230A and Hsp104I230K restricted rescue of toxicity to α-syn and FUS (Figure 5B). 
As with position I187, mutation of I230 to valine (which is often found at position 230 in 
Hsp104 homologs) or proline did not confer potentiation (Figures 4G and 5B). In contrast to 
I187, however, an aspartate substitution at I230 enhanced activity (Figure 5B). None of the 
Hsp104I230X variants exhibited off-target toxicity, with the exception of Hsp104I230D 
(Figure S3B). Thus, mutation of I230 is a safer way to elicit enhanced activity than mutation 
of I187.
Hsp104Q347X rescued α-syn, TDP-43, and FUS toxicity when mutated to leucine, threonine, 
or valine (Figure 5C). There was no rescue of α-syn, FUS, or TDP-43 toxicity when Q347 
was mutated to alanine, asparagine, proline, phenylalanine, aspartate (a residue commonly 
found at this position in Hsp104 homologs), or lysine (Figures 4G and 5C). Thus, 
potentiation of Hsp104 via mutation of Q347 can be conferred through introduction of 
branched amino acids or polar uncharged side chains smaller than asparagine. Remarkably, 
Hsp104Q347X variants did not exhibit off-target toxicity, indicating multiple safe paths to 
Hsp104 potentiation (Figure S3C).
Hsp104E360X displayed the strongest rescue of α-syn, TDP-43, and FUS toxicity when 
mutated to lysine, arginine, or asparagine (Figure 5D). Hsp104E360F suppressed α-syn and 
FUS toxicity but not TDP-43 toxicity (Figure 5D). Phenylalanine is not found naturally at 
position 360 in any Hsp104 homolog. Only the charge-reversing mutations to lysine or 
arginine, or uncharged, polar asparagine conferred broad potentiated activity. Thus, there are 
fewer routes to potentiated Hsp104 activity via mutation of E360. Hsp104E360K exhibited 
minimally reduced growth at 37°C, whereas Hsp104E360F/N/R did not (Figure S3D). In 
contrast, Hsp104E360P, which failed to rescue α-syn, TDP-43, or FUS toxicity (Figure 5D) 
exhibited strong off-target toxicity even at 30°C (Figure S3D). Thus, Hsp104E360P is a toxic 
hyperactive Hsp104 variant, exhibiting even greater toxicity than Hsp104A330V. Mutation of 
E360 can therefore yield toxic hyperactive variants (e.g., E360P) as well as potentiated 
variants with minimal (e.g., E360K) or no toxicity (e.g., E360F).
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Potentiated NBD1 Variants Are Enhanced ATPases, Disaggregases, and Unfoldases
We next purified Hsp104I187F, Hsp104I230N, Hsp104Q347L, and Hsp104E360R and assessed 
their ATPase, disaggregase, and unfoldase activity. The majority of potentiated MD variants 
display higher ATPase activity than Hsp104 (Jackrel et al., 2014a). Indeed, Hsp104A503V 
displays ~5-fold greater ATPase activity than Hsp104 (Jackrel et al., 2014a; Schirmer et al., 
2004). The four NBD1 variants we tested also displayed higher ATPase activity than Hsp104 
(Figure 6A). Hsp104I187F had the highest ATPase activity, ~10-fold higher than Hsp104 and 
~2-fold higher than Hsp104A503V (Figure 6A). Hsp104I230N exhibited similar ATPase 
activity as Hsp104A503V (Figure 6A). The ATPase activity for Hsp104Q347L and 
Hsp104E360R was slightly less than that of Hsp104A503V and Hsp104I230N (Figure 6A). 
Thus, potentiating NBD1 mutations elevate ATPase activity, which may enable more work 
to be performed on substrate per unit time.
We next tested the protein disaggregation and reactivation activity of the NBD1 variants 
using denatured luciferase aggregates (Glover and Lindquist, 1998). Although Hsp104 
requires Hsp70 and Hsp40 for luciferase reactivation (Figure 6B), potentiated MD variants 
do not (Jackrel et al., 2014a). Similar to enhanced MD variants, Hsp104I187F, Hsp104I230N, 
and Hsp104Q347L do not require Hsp70 or Hsp40 for luciferase reactivation (Figure 6B). In 
the absence of Hsp70 and Hsp40, Hsp104I187F, Hsp104I230N, and Hsp104Q347L were 
slightly less active than Hsp104 with Hsp70 and Hsp40 (Figure 6B). Hsp104E360R alone was 
also more active than Hsp104 without Hsp70 and Hsp40, but less active than Hsp104I187F, 
Hsp104I230N, and Hsp104Q347L (Figure 6B). The addition of Hsp70 and Hsp40 to the NBD1 
variants increased luciferase reactivation substantially (Figure 6B). In the presence of Hsp70 
and Hsp40, Hsp104I187F was ~3-fold more active, Hsp104I230N was ~4-fold more active, 
Hsp104Q347L was ~5-fold more active, and Hsp104E360R was ~1.5-fold more active than 
Hsp104 with Hsp70 and Hsp40 (Figure 6B). Thus, collaboration with Hsp70 and Hsp40 
enables optimal disaggregase activity in vitro and also likely in vivo. Nonetheless, 
potentiating NBD1 mutations increase disaggregase activity in the absence or presence of 
Hsp70 and Hsp40.
We next analyzed unfoldase activity. We used the substrate RepA1–70-GFP, where RepA1–70 
serves as an unfolded tag and upon translocation of RepA1–70, the appended GFP moiety is 
unfolded and loses fluorescence. To eliminate confounding effects of spontaneous GFP 
refolding, we used GroELtrap, which prevents GFP refolding (Doyle et al., 2007). Hsp104 
unfolds RepA1–70-GFP in the presence of a 1:1 ratio of ATP:ATPγS but not in the presence 
of ATP alone (Figure 6C; Jackrel et al., 2014a). However, the potentiated NBD1 variants 
Hsp104I187F, Hsp104I230N, Hsp104Q347L, and Hsp104E360R, like the potentiated MD 
variants, unfold RepA1–70-GFP in the presence of only ATP (Figure 6C) (Jackrel et al., 
2014a; Jackrel and Shorter, 2014). The potentiated NBD1 variants unfold RepA1–70-GFP 
more rapidly with ATP than Hsp104 with ATP and ATPγS (Figure 6C). Hsp104I187F and 
Hsp104I230N displayed similar unfoldase activity to Hsp104A503S (a potentiated MD 
variant), whereas Hsp104Q347L and Hsp104E360R were slightly less effective (Figure 6C). 
Thus, potentiating NBD1 mutations enhance unfoldase activity.
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Potentiated NBD1 Variants Confer Thermotolerance but Not Resistance to Azetidine-2-
Carboxylic Acid
We next assessed whether enhanced NBD1 variants generally rendered yeast less sensitive to 
protein aggregation in two ways. First, we assessed thermotolerance to 50°C, at which many 
proteins aggregate and must be solubilized and reactivated (but not degraded) to promote 
viability (Parsell et al., 1994). We found that enhanced Hsp104 variants conferred similar 
thermotolerance to Hsp104 (Figure S4A). There were some exceptions: Hsp104E360K, 
Hsp104E360F, Hsp104E360R, and Hsp104A330V displayed ~2-fold reduced thermotolerance 
(Figure S4A). In contrast, Hsp104I187S and Hsp104I187N conferred an ~60% increase in 
thermotolerance (Figure S4A). Overall, however, enhanced Hsp104 variants were similar to 
Hsp104 in conferring thermotolerance.
Second, we assessed growth on azetidine-2-carboxylic acid (AZC), a toxic proline analog. 
AZC is incorporated into proteins competitively with proline and elicits widespread protein 
aggregation (Trotter et al., 2001; Weids and Grant, 2014). We induced expression of the 
Hsp104 variant prior to plating on AZC. Neither Hsp104 nor enhanced variants rescued 
AZC toxicity (Figure S4B). Thus, enhanced Hsp104 variants do not generally render cells 
less sensitive to toxicity connected to widespread protein aggregation. Rather, they exhibit 
enhanced activity against the selection pressures screened for here (i.e., α-syn, TDP-43, or 
FUS toxicity). We suggest that enhanced Hsp104 variants are better equipped to combat 
aggregation and toxicity of a single dominant protein (e.g., α-syn, TDP-43, or FUS) but 
exhibit similar activity to wild-type when challenged with multiple aggregating proteins as 
in thermotolerance or growth on AZC. Nonetheless, Hsp104 variants that confer greater 
thermotolerance or AZC resistance can likely be found via screens using growth at 50°C or 
growth on AZC as the selection pressure.
Hsp104N566I Is a Potentiated NBD2 Variant
We also generated libraries of NBD2 variants and screened them for rescue of α-syn, 
TDP-43, or FUS toxicity. Remarkably, we uncovered only one potentiated variant, 
Hsp104N5661 (Figures 4A and 4B). Several NBD2 variants with a single missense mutation 
(e.g., H571Q, V581A, V581F, S597A, S618A, S618Y, K654N, G668S, T697S, L703S, 
N728A, N728K, V754I, H781L, K782T, E792K, E793R, R794D, L806V, L877W) were 
unable to rescue α-syn, FUS, and TDP-43 toxicity in yeast (Torrente et al., 2016). The 
difficulty in isolating potentiated NBD2 variants indicates that NBD2 may be less receptive 
to single amino acid changes that enhance Hsp104 activity. Moreover, when we aligned 
Hsp104 NBD1 to NBD2 and made analogous mutations in NBD2 equivalent to the 
potentiating mutations in NBD1, then we also did not observe enhanced activity. Thus, 
V580F (equivalent to I187F), I587T (equivalent to I193T), L631N (equivalent to I230N), 
H781L (equivalent to Q347L), and E793K (equivalent to E360K) did not potentiate Hsp104. 
These findings emphasize the non-equivalent roles that NBD1 and NBD2 play in Hsp104 
disaggregase activity, and likely reflect that NBD1 and NBD2 are from different clades of 
the AAA+ family (Erzberger and Berger, 2006).
N566 is a poorly conserved residue in helix D2 of the NBD2 large domain (Figures 4A, 4B, 
and Figure 7A). Arginine or lysine is typically found at this position in Hsp104 homologs, 
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indicating a divergent feature of S. cerevisiae Hsp104 (Figure 7A). Interestingly, N566 lies 
at the NBD2 protomer interface (Gates et al., 2017; Ye et al., 2019). N566 is in proximity to 
L845 of the neighboring protomer at the P2-P3, P3-P4, P4-P5, and P5-P6 interfaces in the 
extended state of substrate-bound Hsp104 in the presence of ATPγS (Figure 7B; Gates et al., 
2017). In contrast, N566 is shifted away from L845 in most protomers in the closed state of 
substrate-bound Hsp104 in the presence of ATPγS and is only in proximity to L845 at the 
P6-P1 interface (Figure 7B; Gates et al., 2017). Thus, N566I could alter communication 
between adjacent Hsp104 protomers during polypeptide translocation.
Like enhanced NBD1 variants, Hsp104N566I conferred similar thermotolerance to Hsp104 
and was unable to counter AZC toxicity (Figures S4A and S4B). Remarkably, Hsp104N566I 
effectively rescued α-syn, FUS, and TDP-43 toxicity in yeast without grossly affecting 
disease protein expression level and was almost as effective as Hsp104A503V (Figures 7C 
and 7D). Accordingly, Hsp104N566I reduced α-syn aggregation but not as potently as 
Hsp104A503V (Figure S5). Hsp104N566I also reduced the proportion of cells with multiple 
FUS foci but was not as effective as Hsp104A503V or potentiated NBD1 variants at 
eliminating cytoplasmic FUS foci (Figures 3C, 3D, and S6). Thus, the presence of multiple 
FUS foci may be particularly toxic. Unexpectedly, Hsp104N566I does not restore TDP-43 
back to the nucleus like Hsp104A503V (Figure S7), despite rescuing TDP-43 toxicity without 
affecting TDP-43 levels (Figures 7C and 7D). Thus, Hsp104N566I likely rescues TDP-43 
toxicity via another mechanism.
Importantly, Hsp104N566I exhibited similar growth to Hsp104 at 37°C (Figure 7E). 
Hsp104N566I was not toxic like Hsp104A503V at 37°C Figure 7E). Thus, Hsp104N566I is akin 
to non-toxic potentiated NBD1 variants (Figure 3E). Like Hsp104A503V, Hsp104N566I 
exhibited elevated ATPase activity (Figure 7F). However, Hsp104N566I luciferase 
disaggregase activity was not as potent as Hsp104A503V in the presence or absence of Hsp70 
and Hsp40 (Figure 7G). Yet Hsp104N566I luciferase reactivation activity was higher than 
Hsp104 in the absence of Hsp70 and Hsp40 (Figure 7G). Thus, separation of Hsp104 
disaggregase activity from Hsp70 and Hsp40 might enable rescue of α-syn, FUS, and 
TDP-43 toxicity (Jackrel et al., 2014a; Torrente et al., 2016).
DISCUSSION
Here, we define single missense mutations in NBD1 or NBD2 that potentiate Hsp104. 
Potentiated NBD1 and NBD2 variants suppress the toxicity of TDP-43 and FUS (implicated 
in ALS-FTD), as well as α-syn toxicity (implicated in PD), whereas Hsp104 is ineffective. 
Several NBD1 variants also suppressed aggregation of these disease-associated substrates. 
Previously, we isolated numerous missense mutations located at disparate positions 
throughout the Hsp104 MD that confer potentiation (Jackrel et al., 2014a, 2015). Several of 
these potentiating MD mutations likely disrupt inter-protomer MD contacts or intra-
protomer NBD1:MD contacts in the ADP-bound hexamer (Gates et al., 2017; Heuck et al., 
2016). The potentiating NBD1 mutations alter residues that contact ATP (I187, L355), 
contact ATP-binding residues (Q347), or reside at intra-protomer (I230, E360) or inter-
protomer (E190, E360) NBD1:MD interfaces. Importantly, potentiated NBD1 variants do 
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not typically exhibit off-target toxicity, unlike several potentiated MD variants, and thus 
provide a risk-averse mechanism to enhance Hsp104 activity.
We have expanded the repertoire of mutations that enhance Hsp104 activity into the NBD1 
ATP-binding pocket. I187 directly contacts nucleotide, and L355 helps confine nucleotide in 
the nucleotide-binding pocket. Q347 contacts I351, which also directly binds nucleotide 
(Gates et al., 2017; Lee et al., 2003; Yokom et al., 2016). Alteration of these side chains 
likely affects NBD1 activity. Indeed, Hsp104I187F and Hsp104Q347L exhibited elevated 
ATPase activity that was coupled to enhanced disaggregase activity. Interestingly, the 
equivalent mutations in NBD2 did not potentiate activity, which likely reflects that NBD1 
and NBD2 are from different clades of the AAA+ family and may operate differently 
(Sweeny and Shorter, 2016). This finding also reinforces functional differences between 
NBD1 and NBD2 in Hsp104 disaggregase activity (Doyle et al., 2007; Hattendorf and 
Lindquist, 2002b; Schirmer et al., 2001; Torrente et al., 2016).
E190 and E360 are in close contact with the MD of the counterclockwise protomer in the 
AMP-PNP-bound hexamer (Yokom et al., 2016). Thus, mutation of these residues may alter 
NBD1:MD communication between adjacent protomers. Curiously, mutation of several 
other residues that form salt bridges in this inter-protomer NBD1:MD contact in the AMP-
PNP-bound hexamer inactivates Hsp104 (Gates et al., 2017). Thus, residues involved in this 
inter-protomer NBD1:MD contact area are sensitive to mutation, with some mutations 
inactivating Hsp104 (Gates et al., 2017) and other mutations enhancing Hsp104 (this study). 
However, mutating residues in the MD that contact E190 (R419) or E360 (R433) in the 
AMP-PNP-bound hexamer did not potentiate Hsp104. Neither Hsp104R419V nor 
Hsp104R433E rescued TDP-43, FUS, or α-syn toxicity. Thus, the mechanism of potentiation 
may not be as simple as disrupting this inter-protomer NBD1:MD interaction. Notably, 
another residue that can be altered to yield potentiated activity, I193, interacts with E190 in 
the ADP-bound hexamer. Thus, altered E190 or I193 contacts may enhance activity.
NBD1 residues I230 and E360 contact MD residues R495 and K480 respectively in the 
ADP-bound hexamer (Gates et al., 2017). I230N and E360K may perturb these interactions 
and enhance Hsp104 activity. Importantly, R495E and K480E mutations also potentiate 
Hsp104 (Jackrel et al., 2015).Thus, disrupting intra-protomer NBD1:MD interactions in the 
ADP-bound hexamer can enhance Hsp104 activity.
We also expand the landscape of potentiating mutations into NBD2. Far fewer potentiated 
Hsp104 variants emerged from our NBD2 screen compared with our NBD1 or MD screens. 
Thus, NBD2 may be less receptive to single missense mutations that enhance activity. 
Hsp104N566I was the only potentiated NBD2 variant to emerge. Intriguingly, N566 resides in 
the NBD2 protomer interface and could alter inter-protomer communication during substrate 
translocation (Gates et al., 2017). Thus, altering hexamer interfaces in NBD2 can yield 
enhanced activity, delineating another route to potentiated activity that does not appear to 
involve the MD.
Hsp104N566I rescued α-syn aggregation and toxicity. In contrast, Hsp104N566I rescued FUS 
and TDP-43 toxicity without drastically affecting their aggregation. Hsp104N566I reduced 
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the proportion of cells with multiple cytoplasmic FUS foci, which may be critical to mitigate 
FUS toxicity. However, Hsp104N566I had no obvious effect on cytoplasmic TDP-43 foci and 
did not return TDP-43 to the nucleus, unlike enhanced NBD1 variants. Thus, Hsp104N566I 
may rescue TDP-43 toxicity via a distinct mechanism. Hsp104N566I may direct TDP-43 into 
less toxic aggregated structures or material states. Alternatively, Hsp104N566I might 
eliminate toxic, soluble TDP-43 oligomers, while leaving less toxic aggregated structures 
intact. Hsp104N566I might also extract essential proteins whose coaggregation with TDP-43 
contributes to toxicity. These possible mechanisms are not mutually exclusive and may 
combine to rescue toxicity.
Loss of amino acid identity at some positions in the MD can potentiate Hsp104. Indeed, 
mutation of A503 to any residue except proline enabled Hsp104 to potently rescue α-syn, 
FUS, and TDP-43 toxicity (Jackrel et al., 2014a). This same level of degeneracy did not 
apply to our potentiated NBD1 variants. Tighter constraints on NBD1 appear to reduce the 
number of mutagenic routes to enhanced activity. Indeed, not any mutation would potentiate 
at the I187, I230, Q347, or E360 positions. The I187 and I230 positions were the most 
permissive as five residues we assessed at these positions enabled rescue of α-syn, FUS, and 
TDP-43 toxicity. Q347 and E360 were more restrictive with only three residues we tested 
conferring broad-spectrum potentiated activity. These findings refine our understanding of 
disaggregase sequence space and clarify mutagenic routes to potentiated activity. For 
example, there appear to be many possible routes to enhanced activity by mutating A503, 
fewer for I230, and fewer still for E360.
Our findings reveal deep insights into disaggregase mechanism, regulation, therapeutics, and 
evolution. We define how altering NBD1 or NBD2 can enhance Hsp104 activity. We have 
been concerned that the lack of substrate specificity of the variants may lead to the non-
specific unfolding of proteins and off-target toxicity under some conditions, as with many 
potentiated MD variants (Jackrel and Shorter, 2015). However, the majority of potentiated 
NBD1 (I193T, I230N, Q347L, L355A, and E360R) and NBD2 (N566I) variants explored 
did not exhibit reduced growth at 37°C in yeast. Thus, potentiated NBD1 and NBD2 variants 
appear less prone to deleterious off-target effects.
Several distinct misfolded conformers of a single protein can contribute to toxicity in 
neurodegenerative disorders (Chuang et al., 2018; Liu et al., 2016; Rasmussen et al., 2017). 
Moreover, misfolded conformers of different proteins can promote neurodegeneration in the 
same disease (Aoyagi et al., 2019; Robinson et al., 2018). Ideally, we envisage engineering 
Hsp104 variants that selectively purge the entire cloud of diverse toxic conformers to 
remediate disease progression rather than focusing on a single conformer (Mack and 
Shorter, 2016).
The non-toxic, potentiated NBD1 and NBD2 variants uncovered here represent attractive 
variants to advance to animal models. Hsp104 variants could ultimately be developed as 
therapeutics (Jackrel and Shorter, 2015; Lo Bianco et al., 2008; Shorter, 2008, 2017). 
Several strategies can be conceived, including gene-, mRNA-, or protein-based therapies 
(Shorter, 2016, 2017). For example, Hsp104 variants could be delivered via neuron-specific 
adeno-associated viruses (AAVs) that selectively target degenerating neurons (Bedbrook et 
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al., 2018; Chan et al., 2017; Deverman et al., 2016; Tervo et al., 2016). AAVs have key 
advantages including minimal immunogenicity and robust transgene expression in the CNS 
without integration into the host genome (Bedbrook et al., 2018; Hocquemiller et al., 2016). 
Game-changing AAV therapies are now U.S. Food and Drug Administration (FDA) 
approved for congenital blindness and spinal muscular atrophy (Apte, 2018; Mendell et al., 
2017). Ultimately, we envision a therapy in which an inducible disaggregase transgene is 
delivered in a single AAV dose and serves as a long-lasting, lifelong treatment, which can be 
switched on or off as needed by an orally administered drug. This approach is attractive, as 
we desire to only transiently express a therapeutic disaggregase until protein misfolding is 
reversed. Once reversed, then the disaggregase would be silenced to minimize any off-target 
effects or immune response. Should disease resurface, the disaggregase would be switched 
back on. Rapid advances in AAV technology make this approach feasible (Bed-brook et al., 
2018). Finally, lessons learned from tailoring therapeutic Hsp104 disaggregases will prove 
instructive for safely enhancing the activity of several human protein disaggregases, which 
might also be applied to treat neurodegenerative disorders (Guo et al., 2018, 2019; Shorter, 
2011, 2016, 2017).
STAR★METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, James Shorter (jshorter@pennmedicine.upenn.edu). Plasmids 
newly generated in this study will be made readily available to the scientific community. We 
will honor requests in a timely fashion. Material transfers will be made with no more 
restrictive terms than in the Simple Letter Agreement or the Uniform Biological Materials 
Transfer Agreement and without reach through requirements.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Yeast Strains and Media—Yeast were WT W303a (MATa, can1-100, his3-11, 15, 
leu2-3, 112, trp1-1, ura3-1, ade2-1) or the isogenic strain W303aΔhsp104 (Jackrel et al., 
2014a). The yeast strains W303aΔhsp104-pAG303GAL-α-syn-YFP-pAG304GAL-α-syn-
YFP, W303aΔhsp104-pAG303GAL-FUS, W303aΔhsp104-pAG303GAL-TDP-43, 
W303aΔhsp104-pAG303GAL-TDP-43-GFPS11-pAG305GAL-GFPS1-10, and 
W303aΔhsp104-pAG303GAL-FUS-GFP have been previously described (Jackrel et al., 
2014a, 2014b; Jackrel and Shorter, 2014). Yeast were grown in rich media (YPD) or 
synthetic dropout media, supplemented with 2% glucose, raffinose, or galactose.
METHOD DETAILS
Plasmids—QuikChange site-directed mutagenesis (Agilent) was used to create mutations 
in the pAG416GAL-Hsp104, pNOTAG-Hsp104, and pRS313-Hsp104 plasmids (Gates et al., 
2017; Hattendorf and Lindquist, 2002a; Jackrel et al., 2014a). Mutations were confirmed by 
DNA sequencing and are detailed in the Key Resources Table.
Yeast Transformation and Spotting Assays—Figures 1, 2, 3, 5, 7, S1, S2, S3, 
and S4—Yeast transformations were performed using standard polyethylene glycol and 
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lithium acetate procedures (Gietz and Schiestl, 2007). For the spotting assays, yeast were 
grown to saturation in raffinose supplemented dropout media overnight at 30°C. The 
saturated overnight cultures were normalized to an OD600 of 2.0 (A600nm = 2.0) and serially 
diluted five-fold. A 96-bolt replicator tool (frogger) was used to spot the strains in duplicate 
onto both glucose and galactose dropout plates. These plates were grown at 30°C and 
imaged after 72h to assess suppression of disease toxicity. Each spotting assay shown is 
representative of at least two or three biological replicates.
Library Generation and Screening—Library generation and screening were performed 
as described previously (Jackrel et al., 2014a, 2014b). The GeneMorph II EZClone Domain 
Mutagenesis kit (Agilent) was used to create a library of NBD1 or NBD2 mutants, with 
modifications. NBD1 or NBD2 was amplified by PCR using Mutazyme. Gel extraction was 
used to purify the resulting PCR product, and this PCR product was used as the template in a 
PCR reaction containing pRS416GAL-Hsp104WT and PfuUltraII HS polymerase. DpnI 
restriction enzyme was used to digest the parental DNA product, and the product was 
purified using StrataClean resin (Agilent). The product was then ethanol precipitated and 
transformed by electroporation into ElectroMAX DH5α cells in quadruplicate to maintain 
library size. Representative clones were sequenced to confirm mutagenesis of NBD1 or 
NBD2.
The NBD1 or NBD2 library was transformed into yeast containing pAG303GAL-α-syn-
YFP-pAG304GAL-α-syn-YFP, pAG303GAL-FUS, or pAG303GAL-TDP-43 and the yeast 
were harvested and pooled to form the final library. The library was grown overnight in 
raffinose-containing media and then plated onto galactose media. Individual yeast colonies 
were selected for further analysis. A secondary screen was performed to confirm that 
toxicity suppression was Hsp104-dependent. Here, Hsp104 variants were streaked onto 5-
FOA media to counterselect for strains that lost the Hsp104 plasmids. Toxicity of the 
disease-substrate in the absence of Hsp104 was then assessed to validate strains as 
containing true hits (Jackrel et al., 2014a, 2014b). All missense mutations were then 
constructed freshly in the pAG416GAL-Hsp104 template plasmid using QuikChange 
mutagenesis for all additional experiments.
Western Blotting—Figures 1, 2, 3, 7, S1, S2, and S4—Transformed Hsp104 variants 
and controls were grown overnight in raffinose media. The overnight cultures were diluted to 
an OD600 of 0.3 (A600nm = 0.3) and grown in galactose-supplemented media at 30°C. α-
synuclein samples were induced for 8h, while FUS and TDP-43 samples were induced for 
5h. Samples were then normalized to an OD600 of 0.6 (A600nm = 0.6). The pelleted cells 
were resuspended in 0.1 M NaOHfor5 min and then pelleted again and resuspended in 
1xSDS sample buffer. The samples were then boiled and separated by SDS-PAGE (4%–20% 
gradient, Bio-Rad) and transferred to a PVDF membrane. The following primary antibodies 
were used: anti-GFP polyclonal (Sigma-Aldrich), anti-FUS polyclonal (Bethyl 
Laboratories), anti-TDP-43 polyclonal (Proteintech), anti-Hsp104 polyclonal (Enzo Life 
Sciences), and anti-PGK monoclonal (Invitrogen). Two fluorescently labeled secondary 
antibodies were used: anti-rabbit (Li-Cor) and anti-mouse (Li-Cor). Blots were imaged using 
a LI-COR Odyssey FC Imaging system.
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Toxicity Assay—Figures 3, 7, and S3—Hsp104 variants along with applicable controls 
were transformed into W303aΔhsp104 yeast. The strains were grown overnight in raffinose 
dropout media at 30°C with shaking. The saturated cultures were normalized to an OD600 of 
2.0 (A600nm = 2.0) and spotted in duplicate onto two sets of SD-Ura and SGal-Ura plates. 
One set of plates was placed at 37°C and the other at 30°C. Both sets of plates were 
analyzed for toxicity after 72-96h.
Yeast Thermotolerance Assay—Figure S4—pRS313 plasmid encoding the indicated 
Hsp104 variant under the control of the HSP104 promoter or an empty vector control was 
transformed into W303aΔhsp104 yeast as described in the “Yeast Transformation and 
spotting assays” section and plated on Glucose-His-dropout (SD-His) plates. The 
transformants were then inoculated in SD-His media for 4 h at 30°C and normalized to 
OD600 of 0.6 (A600nm = 0.6). Yeast were then incubated at 37°C for 30min to induce Hsp104 
expression, followed by a 0 or 20 min heat shock at 50°C. Yeast were then plated onto SD-
His after a 1000-fold dilution. Yeast colonies were then counted after three days at 30°C 
using an aCOLyte colony counter (Synbiosis). The number of colonies after 20 min heat 
shock was divided by the number of colonies after no heat shock to enable calculation of the 
survival (%) conferred by each Hsp104 variant or the empty vector control.
Yeast L-Azetidine-2-carboxylic acid (AZC) tolerance Assay—Figure S4—
pAG416Gal encoding the indicated Hsp104 variant or empty vector control was transformed 
into W303aΔhsp104 yeast as described in the “Yeast Transformation and spotting assays” 
section and plated on SD-Ura. The transformants were then inoculated in SRaff-Ura media 
and grown overnight until saturation at 30°C. Yeast were then inoculated into SGal-Ura 
media and grown for 6 h at 30°C to induce Hsp104 expression. The samples were then 
normalized to OD600 of 1 and spotted on SD-Ura or SGal-Ura plates containing 0mM, 
2mM, or 5mM AZC as described in the “Spotting assay” section.
Fluorescence Microscopy—Figures 1, 2, 3, S5, S6, and S7—Microscopy samples 
were grown and induced as they were for immunoblotting. For TDP-43 samples 
(W303aΔhsp104-pAG303GAL-TDP-43-GFPS11-pAG305GAL-GFPS-10), cells were 
harvested, fixed in 1mL 70% ethanol, and immediately pelleted. The cells were then washed 
3 times with cold PBS and resuspended in 15μL of Vectashield mounting medium with 4’,6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories). α-syn (W303aΔhsp104-
pAG303GAL-α-syn-YFP-pAG304GAL-α-syn-YFP) and FUS (W303aΔhsp104-
pAG303GAL-FUS-GFP) samples were imaged live. All cells were imaged at 100x 
magnification using a Leica-DMIRBE microscope. Analysis of cells was performed in 
ImageJ (Schneider et al., 2012). For each sample, 97-530 cells were quantified in two or 
three independent trials.
Protein Purification—Protein purification was performed as described previously 
(DeSantis et al., 2014; Jackrel et al., 2014a). Hsp104 proteins were expressed and purified as 
untagged proteins from E. coli. Proteins were overexpressed in BL21(DE3) RIL. Cells were 
harvested, lysed with lysis buffer (50mM Tris pH 8.0,10mM MgCl2, 2.5% glycerol, 2mM β-
mercaptoethanol) supplemented with protease inhibitors, and the protein was purified using 
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Affi-Gel Blue Gel (Bio-Rad). The protein was eluted with elution buffer (50mM Tris pH 
8.0,1M KCl, 10mM MgCl2, 2.5% glycerol, 2mM β-mercaptoethanol). The eluate was buffer 
exchanged into high salt storage buffer (40mM HEPES-KOH pH 7.4, 500mM KCl, 20mM 
MgCl2,10% glycerol, 1mM DTT). The protein was then further purified by ResourceQ 
anion exchange chromatography using running buffer Q (20mM Tris pH 8.0, 0.5mM EDTA, 
5mM MgCl2, 50mM NaCl) and eluted with a linear gradient of buffer Q+ (20mM Tris pH 
8.0, 0.5mM EDTA, 5mM MgCl2, 1M NaCl). Immediately before loading the column, the 
protein was diluted to a final concentration of 10% in buffer Q supplemented to 150mM 
NaCl and loaded onto the column using a 50ml Superloop. The eluted protein was then 
concentrated and exchanged into high salt storage buffer, flash frozen in liquid N2, and 
stored at −80°C until use. Hsp104 concentrations refer to the hexamer concentration. 
RepA1–70-GFP was purified by expressing N-terminally His-tagged protein in E. coli and 
purifying from inclusion bodies in 6M urea. Urea was removed by dialysis and the protein 
was applied to Ni-NTA beads. The eluted protein was then used with the tag. Hsc70 and 
Hdj2 were from Enzo Life Sciences.
ATPase assay—Figure 6—Hsp104 (0.042μM hexamer) was incubated with ATP (1mM) 
for 5min at 25°C. ATPase activity was assessed by the release of inorganic phosphate, which 
was determined using a malachite green phosphate detection kit (Innova). Background 
hydrolysis was determined at time zero and subtracted.
Luciferase Reactivation assay—Figure 6—Luciferase reactivation was performed as 
described (DeSantis et al., 2012; Glover and Lindquist, 1998; Lo Bianco et al., 2008). 
Briefly, to assemble aggregates, firefly luciferase (50μM, Sigma) in luciferase-refolding 
buffer (LRB: 25mM HEPES-KOH pH 7.4, 150mM KAOc, 10mM MgAOc, 10mM DTT) 
plus 8M urea was incubated at 30°C for 30min. The sample was then rapidly diluted 100-
fold into LRB. Aliquots were snap frozen and stored at −80°C until use. Aggregated 
luciferase (50nM) was incubated with Hsp104 (0.167μM hexamer) with ATP (5.1mM) and 
an ATP regeneration system (1mM creatine phosphate, 0.25μM creatine kinase) in the 
presence or absence of Hsc70 (0.167mM) and Hdj2 (0.167mM) for 90min at 25°C. At the 
end of the reaction, luciferase activity was assessed with a luciferase assay system 
(Promega). Recovered luminescence was monitored using a Tecan Infinite M1000 plate 
reader.
RepA1-70-GFP Unfolding Assay—Figure 6—RepA1–70-GFP unfolding was performed 
as described (Jackrel et al., 2014a). Unfolding assays were performed in buffer A (20mM 
Tris-HCl, pH 7.5, 100mM KCl, 0.1mM EDTA, 10% (v/v) glycerol, 20 mg/ml BSA, 0.005% 
(vol/vol) Triton X-100, 10mM MgCl2, and 5mM DTT) in the presence of 20mM creatine 
phosphate, 60 mg/ml creatine kinase and 4mM ATP. RepA1–70-GFP (0.7μM) was incubated 
with the indicated Hsp104 variant (2.1 μM) plus GroELtrap (2.5 μM). Fluorescence was 
monitored using a plate reader (TECAN) with an excitation wavelength at 395nm and 
emission wavelength at 51 nm every min for 60 min. F0 denotes the fluorescence of a 
sample at time = 0. F denotes fluoresce at any time T. F/F0 as a function of time was plotted.
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QUANTIFICATION AND STATISTICAL ANALYSIS
As described in the figure legends, all data points in each graph are means ± standard error 
of the mean (SEM), unless otherwise indicated. For yeast experiments, n represents a 
biological replicate. For biochemical experiments, n represents an independent experimental 
trial. N is indicated in the figure legends. No tests of statistical significance were employed 
in this study.
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Highlights
• Mining Hsp104 sequence space to safely enhance disaggregase activity
• Non-toxic NBD1 and NBD2 variants counter TDP-43, FUS, and α-synuclein 
toxicity
• Mutating NBD1 residues that engage ATP or ATP-binding residues 
potentiates activity
• Mutating the NBD2 protomer interface can safely ameliorate Hsp104 activity
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Figure 1. Hsp104 NBD1 Variants Suppress α-syn Toxicity, Aggregation, and Mislocalization
(A) Domain map of Hsp104 shows the location of potentiating mutations in NBD1 (dark 
blue) and NBD2 (light blue). A503V is in the MD (green). Pink, NTD; brown, CTD.
(B) NBD1 variants suppress α-syn toxicity in yeast. W303aΔhsp104-pAG-303GAL-α-syn-
YFP-304GALα-syn-YFP yeast were transformed with Hsp104 variants or vector. Strains 
were serially diluted 5-fold and spotted in duplicate onto glucose (non-inducing) and 
galactose (inducing) media.
(C) NBD1 variants do not reduce α-syn expression in yeast. Strains in (B) were induced for 
8 h, lysed, and immunoblotted for Hsp104, α-syn, and 3-phosphoglycerate kinase (PGK; 
loading control).
(D) NBD1 variants suppress α-syn aggregation and mislocalization in yeast. Selected strains 
in (B) were induced for 8 h and prepared for fluorescence microscopy. Scale bar, 2.5 μm.
(E) α-syn aggregation and localization were quantified by calculating the proportion of cells 
exhibiting either cytoplasmic aggregates or plasma membrane localization. Values represent 
means ± SEM (n = 3).
See also Figures S1 and S2.
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Figure 2. Hsp104 NBD1 Variants Suppress TDP-43 Toxicity, Aggregation, and Mislocalization
(A) NBD1 variants suppress TDP-43 toxicity in yeast. W303aΔhsp104-pAG-303GAL-
TDP-43 yeast were transformed with Hsp104 variants or vector. Strains were serially diluted 
5-fold and spotted in duplicate onto glucose (non-inducing) and galactose (inducing) media.
(B) NBD1 variants do not reduce TDP-43 expression in yeast. Strains in (A) were induced 
for 5 h, lysed, and immunoblotted for Hsp104, TDP-43, and PGK (loading control).
(C) NBD1 variants suppress TDP-43 aggregation and mislocalization in yeast. Fluorescence 
microscopy of cells coexpressing fluorescently tagged TDP-43 and Hsp104 variants. Strains 
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were induced for 5 h in galactose, fixed, and stained with DAPI (blue) to visualize nuclei. 
Scale bar, 2.5 μm.
(D) TDP-43 localization was quantified by calculating the proportion of cells containing 
colocalized nuclear staining. Values represent means ± SEM (n = 3).
See also Figures S1 and S2.
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Figure 3. Hsp104 NBD1 Variants Suppress FUS Toxicity and Aggregation
(A) NBD1 variants suppress FUS toxicity in yeast. W303aΔhsp104-pAG-303GAL-FUS 
yeast were transformed with Hsp104 variants or vector. Strains were serially diluted 5-fold 
and spotted in duplicate onto glucose (non-inducing) and galactose (inducing) media.
(B) NBD1 variants do not grossly reduce FUS expression in yeast. Strains in (A) were 
induced for 5 h, lysed, and immunoblotted for Hsp104, FUS, and PGK (loading control).
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(C) NBD1 variants suppress FUS aggregation in yeast. Fluorescence microscopy of cells 
coexpressing FUS-GFP and Hsp104 variants. Strains were induced for 5 h in galactose and 
imaged. Scale bar, 2.5 μm.
(D) FUS aggregation was quantified by calculating the proportion of cells containing 
multiple foci, a single focus, or no foci. Values represent means ± SEM (n = 2–3).
(E) Potentiated NBD1 variants typically do not exhibit reduced growth at 37°C. Hsp104 
variants were expressed in the 416GAL vector in Δhsp104 yeast in the absence of any 
disease protein. Strains were serially diluted 5-fold and spotted in duplicate onto glucose 
(non-inducing) and galactose (inducing) media and grown at 30°C or 37°C.
See also Figures S1 and S2.
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Figure 4. Location of Potentiating NBD1 and NBD2 Mutations
(A) Domain map of Hsp104 shows the location of potentiating mutations in NBD1 (dark 
blue) and NBD2 (light blue). A503V is located in the MD (green). Pink, NTD; brown, CTD.
(B) Location of residues in NBD1 and NBD2 that can be mutated to potentiate Hsp104 are 
shown on the hexameric structure of Hsp104 bound to AMP-PNP (left; PDB: 5KNE) and 
bound to ADP (right; PDB: 5VY8). Protomer3(P3) is colored to denote the different 
domains: pink, NTD; dark blue, NBD1; green, MD; and light blue, NBD2 (as in A). P1, P2, 
P4, P5, and P6 are in gray.
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(C–F) Zooms to show the positions of residues that can be mutated to potentiate Hsp104. (C) 
Top views showing the positions of E190 and E360 in P3 of the Hsp104 hexamer in AMP-
PNP (left; PDB: 5KNE) and ADP (right; PDB: 5VY8). (D) Sideviews showing the positions 
of I193 and E190 in P3 of the Hsp104 hexamer bound to AMP-PNP (left; PDB: 5KNE) and 
bound to ADP (right; PDB: 5VY8). (E) Topviews showing the positions of I187 and Q347 
in P3 of the Hsp104 hexamer in AMP-PNP (left; PDB: 5KNE) and ADP (right; PDB: 
5VY8). (F) Side views showing the positions of I230 and L355 in P3 of the Hsp104 hexamer 
in AMP-PNP (left; PDB: 5KNE) and ADP (right; PDB: 5VY8).
(G) Clustal Omega (Sievers and Higgins, 2018) alignment of portions (residues 185–195, 
225–235, 342–352, and 355–365) of NBD1 from Saccharomyces cerevisiae Hsp104 with S. 
cerevisiae Hsp78, Schizosaccharomyces pombe Hsp104, Chlamydomonas reinhardtii 
Hsp104, Arabidopsis thaliana Hsp101, Monosiga brevicollis Hsp104, Thermus thermophilus 
ClpB, Escherichia coli ClpB, and E. coli ClpA. I187, E190, I193, I230, Q347, L355, and 
E360 are indicated with red arrowheads and highlighted in yellow. Asterisk denotes fully 
conserved residue, colon denotes conservation of residues with strong similarity, and period 
indicates conservation of residues with weak similarity.
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Figure 5. Diverse Mutations at Certain NBD1 Sites Potentiate Hsp104
(A) Hsp104 variants mutated at the I187 position and controls were transformed into 
W303aΔhsp104 yeast harboring α-syn (left), TDP-43 (center), or FUS (right) genes. Strains 
were serially diluted 5-fold and spotted in duplicate onto glucose (non-inducing) or 
galactose (inducing) media.
(B–D) Hsp104 variants mutated at the I230 position (B), Q347 position (C), or E360 
position (D) were assessed as in (A).
See also Figures S3.
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Figure 6. Potentiated NBD1 Variants Display Enhanced ATPase, Disaggregase, and Unfoldase 
Activity
(A) NBD1 variants exhibit elevated ATPase activity. Values represent means ± SEM (n = 2–
3).
(B) NBD1 variants exhibit elevated disaggregase activity. Luciferase aggregates were 
incubated with Hsp104 variant plus (gray bars) or minus (black bars) Hsc70 (0.167 μM) and 
Hdj2 (0.167 μM). Values represent means ± SEM (n = 2–7).
(C) NBD1 variants exhibit elevated unfoldase activity. RepA1–70-GFP was incubated with 
Hsp104 variant and GroELtrap plus ATP or ATP:ATPγS (1:1). GFP unfolding was measured 
by fluorescence. Representative data from three trials are shown.
See also Figures S4.
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Figure 7. Hsp104N566I Is a Potentiated NBD2 Variant
(A) Clustal Omega (Sievers and Higgins, 2018) alignment of a portion (residues 561–571) 
of NBD2 from S. cerevisiae Hsp104 with S. cerevisiae Hsp78, S. pombe Hsp104, C. 
reinhardtii Hsp104, A. thaliana Hsp101, M. brevicollis Hsp104, T. thermophilus ClpB, E. 
coli ClpB, and E. coli ClpA. N566 is indicated with a red arrowhead and highlighted in 
yellow. Asterisk denotes fully conserved residue, colon denotes conservation of residues 
with strong similarity, and period indicates conservation of residues with weak similarity.
(B) Bottom-up view of Hsp104 hexamers bound to ATPγS and casein in the extended state 
(top panel; PDB: 5VYA) or closed state (bottom panel; PDB: 5VJH). Protomer 1 (P1) is 
shown in red, P2 in orange, P3 in green, P4 in cyan, P5 in blue, and P6 in purple. N566I lies 
in close proximityto L845 in the neighboring subunit at the P2-P3, P3-P4, P4-P5, and P5-P6 
subunit interfaces in the extended state bound to casein (top panel). In contrast, N566I lies in 
close proximity to L845 in the neighboring subunit at the P6-P1 interface in the closed state 
(bottom panel).
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(C) Hsp104N566I rescues α-syn, FUS, and TDP-43 toxicity in yeast. W303aΔhsp104 yeast 
were transformed with α-syn, FUS, orTDP-43 and Hsp104 variants or vector. Strains were 
serially diluted 5-fold and spotted in duplicate onto glucose (non-inducing) and galactose 
(inducing) media.
(D) Hsp104N566I does not grossly reduce α-syn, FUS, or TDP-43 expression in yeast. 
Strains in (A) were induced for 5 h (FUS and TDP-43) or 8h (α-syn), lysed, and 
immunoblotted. PGK serves as a loading control.
(E) Hsp104N566I does not exhibit reduced growth at 37°C. Hsp104 variants were expressed 
in the 416GAL vector in W303aΔhsp104 yeast in the absence of any disease protein. Strains 
were serially diluted 5-fold and spotted onto galactose (inducing) media and analyzed at 
30°C or 37°C.
(F) Hsp104N566I exhibits elevated ATPase activity. Values represent means ± SEM (n = 3).
(G) Hsp104N566I exhibits elevated disaggregase activity in the absence of Hsp70 and Hsp40. 
Luciferase aggregates were incubated with Hsp104 variant plus (checkered bars) or minus 
(clear bars) Hsc70 (0.167 μM) and Hdj2 (0.167 μM). Values represent means ± SEM (n = 3).
See also Figures S5–S7.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-Hsp104 Enzo Cat#ADI-SPA-1040; RRID: AB_10631415
Mouse monoclonal anti-PGK Invitrogen Cat#459250; RRID: AB_2532235
Rabbit polyclonal anti-GFP Sigma-Aldrich Cat#G1544; RRID: AB_439690
Rabbit polyclonal anti-TDP-43 Proteintech Cat#10782-2-AP; RRID: AB_615042
Rabbit polyclonal anti-FUS Bethyl Laboratories Cat#A300-302A; RRID: AB_309445
Goat anti-rabbit secondary antibody Li-cor Cat#926-68071; RRID: AB_10956166
Goat anti-mouse secondary antibody Li-cor Cat#926-32210; RRID: AB_621842
Bacterial and Virus Strains
BL21(DE3)RIL cells Agilent Cat#230245
XL10-Gold cells Agilent Cat#200314
One Shot TOP10 Chemically Competent E. coli Invitrogen Cat#C404010
ElectroMAX DH5α-E Competent Cells Invitrogen Cat#11-319-019
Chemicals, Peptides, and Recombinant Proteins
Affi-Gel Blue Gel Bio-Rad Cat#1537302
Hsc70 Enzo Cat#ADI-SPP-751
Hdj2 Enzo Cat#ADI-SPP-405
Firefly luciferase Sigma-Aldrich Cat#L6876 Cat# SRE0045
Luciferase Assay Reagent Promega Cat#E1483
Creatine kinase Roche Cat# 10127566001
Creatine phosphate Roche Cat# 10621722001
Adenosine-5’-triphosphate disodium salt hydrate, 98% Alfa Aesar Cat# J61125
Adenosine 5′-[ã-thio]triphosphate tetralithium salt Roche Cat#10102342001
Hsp104 (Jackrel et al., 2014a) N/A
Hsp104A503V (Jackrel et al., 2014a) N/A
Hsp104I187F This paper N/A
Hsp104I230N This paper N/A
Hsp104Q347L This paper N/A
Hsp104E360R This paper N/A
Hsp104N566I This paper N/A
RepA11-70-GFP (Jackrel et al., 2014a) N/A
GroELtrap (Jackrel et al., 2014a) N/A
L-Azetidine-2-carboxylic acid Bachem Cat#4019045
Vectashield mounting medium with DAPI Vector Laboratories Cat#H-1200
5-Fluoroorotic acid (5-FOA) Research Products International Cat#F10501
StrataClean Resin Agilent Cat#400714
DpnI New England Biolabs R0176S
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REAGENT or RESOURCE SOURCE IDENTIFIER
PfuUltra II Fusion HS DNA Polymerase Agilent 600672
Critical Commercial Assays
Pi ColorLock Gold Phosphate Detection System Innova Cat#303-0030
GeneMorph II EZClone Domain Mutagenesis kit Agilent Cat#200552
Experimental Models: Organisms/Strains
S. cerevisiae: W303a (MATa, can1-100, his3-11, 15, leu2-3, 
112, trp1-1, ura3-1, ade2-1) (Schirmer et al., 2004) N/A
S. cerevisiae: W303aΔhsp104 (MATa, can1-100, his3-11, 
15, leu2-3, 112, trp1-1, ura3-1, ade2-1, hsp104::KanMX) (Schirmer et al., 2004) A3224
S. cerevisiae: W303aΔhsp104-pAG303GAL-α-syn-YFP-
pAG304GAL-α-syn-YFP (Jackrel et al., 2014a) N/A
S. cerevisiae: W303aΔhsp104-pAG303GAL-TDP-43 (Jackrel et al., 2014a) N/A
S. cerevisiae: W303aΔhsp104-pAG303GAL-FUS (Jackrel et al., 2014a) N/A
S. cerevisiae: W303aΔhsp104-pAG303GAL-TDP-43-
GFPS11-pAG305GAL-GFPS1-10 (Jackrel et al., 2014a) N/A
S. cerevisiae: W303aΔhsp104-pAG303GAL-FUS-GFP (Jackrel et al., 2014a) N/A
Recombinant DNA
pAG416Gal-CCDB (Jackrel et al., 2014a) N/A
pAG416Gal-Hsp104 (Jackrel et al., 2014a) N/A
pAG416Gal-Hsp104A503V (Jackrel et al., 2014a) N/A
pAG416Gal-Hsp104I187F This paper N/A
pAG416Gal-Hsp104I230N This paper N/A
pAG416Gal-Hsp104Q347L This paper N/A
pAG416Gal-Hsp104E360K This paper N/A
pAG416Gal-Hsp104A178D This paper N/A
pAG416Gal-Hsp104E190V This paper N/A
pAG416Gal-Hsp104I193L This paper N/A
pAG416Gal-Hsp104I193T This paper N/A
pAG416Gal-Hsp104T196S This paper N/A
pAG416Gal-Hsp104L355A This paper N/A
pAG416Gal-Hsp104A330V This paper N/A
pAG416Gal-Hsp104N566I This paper N/A
pAG416Gal-Hsp104R419V This paper N/A
pAG416Gal-Hsp104R495N This paper N/A
pAG416Gal-Hsp104R495E This paper N/A
pAG416Gal-Hsp104R433E This paper N/A
pAG416Gal-Hsp104K480E (Jackrel et al., 2015) N/A
pAG416Gal-Hsp104R433K This paper N/A
pAG416Gal-Hsp104R433Y This paper N/A
pAG416Gal-Hsp104R495D This paper N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
pAG416Gal-Hsp104R495M This paper N/A
pNOTAG-Hsp104 (Hattendorf and Lindquist, 2002a) N/A
pNOTAG-Hsp104A503V (Jackrel et al., 2014a) N/A
pNOTAG-Hsp104I187F This paper N/A
pNOTAG-Hsp104I230N This paper N/A
pNOTAG-Hsp104Q347L This paper N/A
pNOTAG-Hsp104E360R This paper N/A
pNOTAG-Hsp104N566I This paper N/A
pAG416Gal-Hsp104I187A This paper N/A
pAG416Gal-Hsp104I187S This paper N/A
pAG416Gal-Hsp104I187V This paper N/A
pAG416Gal-Hsp104I187P This paper N/A
pAG416Gal-Hsp104I187Y This paper N/A
pAG416Gal-Hsp104I187W This paper N/A
pAG416Gal-Hsp104I187D This paper N/A
pAG416Gal-Hsp104I187N This paper N/A
pAG416Gal-Hsp104I187K This paper N/A
pAG416Gal-Hsp104I230A This paper N/A
pAG416Gal-Hsp104I230S This paper N/A
pAG416Gal-Hsp104I230V This paper N/A
pAG416Gal-Hsp104I230P This paper N/A
pAG416Gal-Hsp104I230F This paper N/A
pAG416Gal-Hsp104I230D This paper N/A
pAG416Gal-Hsp104I230Q This paper N/A
pAG416Gal-Hsp104I230K This paper N/A
pAG416Gal-Hsp104Q347A This paper N/A
pAG416Gal-Hsp104Q347T This paper N/A
pAG416Gal-Hsp104Q347V This paper N/A
pAG416Gal-Hsp104Q347P This paper N/A
pAG416Gal-Hsp104Q347F This paper N/A
pAG416Gal-Hsp104Q347D This paper N/A
pAG416Gal-Hsp104Q347N This paper N/A
pAG416Gal-Hsp104Q347K This paper N/A
pAG416Gal-Hsp104E360A This paper N/A
pAG416Gal-Hsp104E360T This paper N/A
pAG416Gal-Hsp104E360V This paper N/A
pAG416Gal-Hsp104E360P This paper N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
pAG416Gal-Hsp104E360F This paper N/A
pAG416Gal-Hsp104E360D This paper N/A
pAG416Gal-Hsp104E360N This paper N/A
pAG416Gal-Hsp104E360R This paper N/A
pRS313-CCDB (Gates et al., 2017) N/A
pRS313-Hsp104 (Gates et al., 2017) N/A
pRS313-Hsp104A503V This paper N/A
pRS313-Hsp104I187F This paper N/A
pRS313-Hsp104I230N This paper N/A
pRS313-Hsp104Q347L This paper N/A
pRS313-Hsp104E360K This paper N/A
pRS313-Hsp104I193T This paper N/A
pRS313-Hsp104L355A This paper N/A
pRS313-Hsp104N566I This paper N/A
pRS313-Hsp104A330V This paper N/A
pRS313-Hsp104E360F This paper N/A
pRS313-Hsp104I187S This paper N/A
pRS313-Hsp104I187N This paper N/A
pRS313-Hsp104E360R This paper N/A
pRS416GAL-Hsp104 (Jackrel et al., 2014a)
Software and Algorithms
ImageJ (Schneider et al., 2012) https://imagej.nih.gov/ij/
GraphPad Prism GraphPad Version 8.0
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